Jason Gerberry
Stock Analyst at B of A Securities
(3.46)
# 676
Out of 4,829 analysts
160
Total ratings
53.51%
Success rate
0.94%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $16.93 | +29.95% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $31.16 | +339.67% | 9 | Apr 1, 2025 | |
| IMVT Immunovant | Maintains: Buy | $38 → $33 | $14.02 | +135.38% | 5 | Mar 20, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $8.77 | +14.03% | 3 | Feb 28, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $143 → $167 | $107.76 | +54.97% | 5 | Feb 11, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $23.37 | +28.37% | 2 | Jan 9, 2025 | |
| EXEL Exelixis | Downgrades: Neutral | $35 → $39 | $36.17 | +7.82% | 2 | Dec 17, 2024 | |
| BLUE bluebird bio | Downgrades: Neutral | $60 → $10 | $3.50 | +185.71% | 8 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $57.55 | +73.76% | 4 | Nov 6, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $20.24 | +206.32% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $3.00 | +700.00% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $0.72 | +318.59% | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $32.30 | +110.56% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $18.58 | +7.64% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $25.31 | +22.48% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $0.10 | +11,101.63% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $30.13 | -3.75% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $13.03 | +183.96% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $35.02 | +59.91% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $34.06 | -11.91% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $24.18 | +160.55% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $97.78 | +121.93% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $0.31 | +549.35% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $734.57 | -31.93% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.16 | +675.86% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $8.71 | +187.03% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.68 | +197.62% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $4.59 | +488.24% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $0.97 | +1,964.62% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.44 | +2,172.73% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $184.60 | -48.54% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $46.45 | +29.17% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $22.28 | +66.07% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $75.97 | +18.47% | 11 | Oct 17, 2019 |
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $16.93
Upside: +29.95%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $31.16
Upside: +339.67%
Immunovant
Mar 20, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $14.02
Upside: +135.38%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $8.77
Upside: +14.03%
Axsome Therapeutics
Feb 11, 2025
Maintains: Buy
Price Target: $143 → $167
Current: $107.76
Upside: +54.97%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $23.37
Upside: +28.37%
Exelixis
Dec 17, 2024
Downgrades: Neutral
Price Target: $35 → $39
Current: $36.17
Upside: +7.82%
bluebird bio
Nov 15, 2024
Downgrades: Neutral
Price Target: $60 → $10
Current: $3.50
Upside: +185.71%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $57.55
Upside: +73.76%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $20.24
Upside: +206.32%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $3.00
Upside: +700.00%
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.72
Upside: +318.59%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $32.30
Upside: +110.56%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $18.58
Upside: +7.64%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $25.31
Upside: +22.48%
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.10
Upside: +11,101.63%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $30.13
Upside: -3.75%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $13.03
Upside: +183.96%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $35.02
Upside: +59.91%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $34.06
Upside: -11.91%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $24.18
Upside: +160.55%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $97.78
Upside: +121.93%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.31
Upside: +549.35%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $734.57
Upside: -31.93%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.16
Upside: +675.86%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $8.71
Upside: +187.03%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.68
Upside: +197.62%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $4.59
Upside: +488.24%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $0.97
Upside: +1,964.62%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.44
Upside: +2,172.73%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $184.60
Upside: -48.54%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $46.45
Upside: +29.17%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $22.28
Upside: +66.07%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $75.97
Upside: +18.47%